Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Proc (Bayl Univ Med Cent) ; 29(3): 321-2, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27365886

ABSTRACT

Mammary myofibroblastoma is a rare mesenchymal neoplasm that typically presents in older men and women. Less commonly, these benign tumors may also occur in soft tissues located outside of the breast, in which case they are referred to as mammary-type myofibroblastomas. The histologic composition of this benign spindle cell tumor can be markedly varied. We present a case of a large mammary myofibroblastoma in a male patient and discuss the typical imaging and histologic makeup of these tumors.

3.
J Cutan Pathol ; 42(5): 329-32, 2015 May.
Article in English | MEDLINE | ID: mdl-25726718

ABSTRACT

BACKGROUND: One cause of chronic urticaria is autoreactivity which is diagnosed by detecting autoantibodies against the IgE receptor alpha subunit (anti-Fc R1alpha). OBJECTIVE: To compare the histopathologic features of chronic urticaria patients testing positive for anti-IgE receptor antibody (Ab) to those testing negative. METHODS: Totally, 438 patients with a clinical presentation of chronic urticaria (2011-2013) had anti-IgE receptor Ab tested and 37 of those patients had skin biopsy. We evaluated microscopic features including: spongiosis, dermal edema, presence of mast cells, density of lymphocytic infiltration, predomination of eosinophils/neutrophils; intravascular neutrophils and presence of vasculitis. The aforementioned features were compared between negative and positive anti-IgE receptor Ab groups. RESULTS: Of 37 patients , 69% were women and 31% were men. 49% had positive anti-IgE receptor Ab and 51% had negative anti-IgE receptor Ab. In the positive anti-IgE receptor Ab group, 83% showed intravascular neutrophils. Eosinophil predominance was identified in 72% and neutrophil predominance was identified in 28%. In the negative anti-IgE receptor Ab group, 89% showed intravascular neutrophils. Eosinophil predominance was identified in 53% and neutrophil predominance was identified in 47%. There was no evidence of vasculitis in either group. CONCLUSION: There were no significant histopathologic differences between the anti-IgE receptor Ab positive and negative cases. Therefore, serum testing for anti-IgE receptor Ab is required to identify this subgroup of chronic urticaria patients.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Autoantibodies/immunology , Receptors, IgE/immunology , Urticaria/immunology , Urticaria/pathology , Adult , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Chronic Disease , Eosinophils/immunology , Female , Humans , Male , Mast Cells/immunology , Mast Cells/pathology , Middle Aged , Neutrophils/immunology , Skin/pathology
4.
J Cutan Pathol ; 40(10): 884-6, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23924408

ABSTRACT

BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis. We report a case of a patient undergoing BRAF inhibition therapy for disseminated melanoma with a V600E mutation who developed bilateral areolar leiomyomas, one of which was biopsied and the other of which resolved after discontinuation of vemurafenib therapy. To our knowledge, this is the first reported case of a mesenchymal neoplasm developing in association with BRAF inhibition therapy.


Subject(s)
Indoles/adverse effects , Leiomyoma/chemically induced , Leiomyoma/pathology , Melanoma/drug therapy , Neoplasms, Second Primary/pathology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Sulfonamides/adverse effects , Aged , Amino Acid Substitution , Humans , Indoles/administration & dosage , Leiomyoma/enzymology , Male , Melanoma/enzymology , Melanoma/pathology , Mutation, Missense , Neoplasms, Second Primary/enzymology , Sulfonamides/administration & dosage , Vemurafenib
SELECTION OF CITATIONS
SEARCH DETAIL
...